As another tick season settles in across Greater Boston, Pfizer is betting that its experimental Lyme disease vaccine could eventually change the game. The shot is still in testing and years away from pharmacy shelves, but it would be the first Lyme vaccine for humans since the last one disappeared from the market in 2002. For outdoor workers, parents and pet owners, that is more than a scientific curiosity, it is something to keep a very close eye on, as per Pfizer.
What Pfizer announced
The vaccine, called VLA15 and co-developed with French biotech Valneva, is in late-stage clinical trials. According to Pfizer, participants finished the three-dose primary series in mid-2024. If the data cooperate, the company plans to file a Biologics License Application with the U.S. Food and Drug Administration and a Marketing Authorization Application with the European Medicines Agency in 2026.
How the shot works
VLA15 is a protein-subunit vaccine that targets outer surface protein A (OspA), a molecule on the Lyme-causing Borrelia bacteria. The idea is that vaccinated people generate antibodies that can neutralize the bacteria inside a feeding tick before it has a chance to move into the human host. Phase 2 and booster results published in Lancet Infectious Diseases reported strong immune responses along with a tolerable safety profile across age groups, which is the foundation for the current Phase 3 field trials.
Why New England cares
Lyme disease is already a familiar headache in the Northeast. Researchers estimate that roughly 476,000 Americans are diagnosed and treated for Lyme disease each year, underscoring its public health footprint. In Massachusetts, state surveillance has documented rising case counts in recent seasons, and public health officials keep detailed tick-borne disease summaries for residents who want to dig into the numbers. The scale of Lyme nationally and regionally is part of what makes a potential vaccine especially relevant for Boston-area residents and those who work outside. The estimates and local tracking behind these concerns are detailed in CDC Emerging Infectious Diseases.
Trial status and the timeline
Valneva told investors in a February update that the first Phase 3 data readout for VLA15 is expected in the first half of 2026, with regulatory filings to follow if the results line up with Pfizer's plans. Industry coverage has noted that the VALOR study enrolled thousands of volunteers in Lyme-endemic regions across the United States, Canada and Europe to gauge how well the vaccine works outside the lab. Enrollment figures and the overall timetable are laid out in Valneva's report to investors at Valneva and in coverage by BioPharma Dive.
Past doubts still matter
Any new Lyme vaccine has to contend with the ghost of LYMErix, the only human Lyme shot ever licensed in the United States. That vaccine was withdrawn in 2002 amid declining sales and lawsuits, and its messy exit has influenced how both the public and the pharmaceutical industry view Lyme vaccine projects today. Background on LYMErix and why companies stepped so carefully afterward is summarized by the National Institute of Allergy and Infectious Diseases. NIAID lays out the history of that era and the caution that followed.
What locals should do this tick season
For now, prevention is still very much a do-it-yourself project. Public health officials continue to push the basics: daily tick checks after being outdoors, treating clothing with permethrin for high-risk activities, choosing EPA-registered repellents and removing attached ticks quickly with fine-tipped tweezers. The Massachusetts Department of Public Health provides local surveillance summaries and step-by-step guidance for residents and employers gearing up for spring and summer outside. Region-specific prevention advice is available at Mass.gov.
Pfizer's public comments on VLA15 have been framed as cautious optimism rather than a victory lap, a reminder that the data and regulators still have the final say before any vaccine shows up at local doctors' offices. For on-the-ground coverage and video from the area, visit CBS Boston.
